Agent Orange benefits extended to vets with B-cell cancers

Working in conjunction with the Institute of Medicine, the U.S. Department of Veterans Affairs (VA) Secretary Eric Shinseki announced that the VA is expanding the list of conditions and diseases "acknowledged as having a connection to being exposed to Agent Orange."

The new additions: ischemic heart disease, Parkinson's disease, and all B-cell blood cancers.

Associated conditions already on the VA's list: Hodgkin's, chronic lymphocytic leukemia, and Non-Hodgkin’s Lymphoma, described by the VA as "a diverse group of hematologic (blood) cancers including any lymphoma (cancer of the lymph system) other than Hodgkin's Lymphoma that affect the lymph glands and other lymphatic tissue."

Anyway, by my count, these new B-cell benefits should extend to vets diagnosed with:
- Diffuse large B-cell lymphoma (DLBCL)
- Hairy cell leukemia
- Extranodal marginal-zone B-cell (MALT) lymphoma
- Lymphoplasmacytoid lymphoma
- Splenic marginal zone lymphoma
- Nodal marginal-zone B-cell (MALT) lymphoma
- Mantle cell lymphoma
- Follicular lymphoma
- Burkitt's lymphoma

One of the most hideous and unremitting legacies of the Vietnam war, over 21 million gallons of the herbicide Agent Orange was sprayed to excess by the US military for over 5 years beginning in 1965 to kill that country's thick foliage and prevent the enemy from hiding amongst it. Today the VA estimates that over 2.5 million military personnel were potentially exposed to the horrible chemical.

Meanwhile, the Vietnamese government has estimated that Agent Orange has killed or maimed 400,000; that it has given half a million children birth defects; and that another 2 million have developed diseases like cancer.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap